Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

Charles L. Groomes, David M. Gianferante, Gary D. Crouch, Dina S. Parekh, David W. Scott, Kenneth Lieuw*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time- and resource-intensive immune tolerance induction (ITI) protocols. We report a 15-month-old male with severe HA and a high-titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half-life rFVIII-Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.

Original languageEnglish
Pages (from-to)922-924
Number of pages3
JournalPediatric Blood and Cancer
Volume63
Issue number5
DOIs
StatePublished - 1 May 2016
Externally publishedYes

Keywords

  • Eloctate
  • Factor VIII inhibitors
  • Hemophilia A
  • Immune tolerance induction
  • Recombinant factor VIII-Fc fusion protein

Fingerprint

Dive into the research topics of 'Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein'. Together they form a unique fingerprint.

Cite this